Is Eris Lifesciences (ERIS) overvalued or fairly valued?

MarketChacha shows Eris Lifesciences's valuation in context — a forward P/E of about 23.6, a price-to-book of about 5.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Eris Lifesciences's revenue?

Eris Lifesciences reported revenue of ₹3,129 Cr for FY2026, with net profit of ₹620 Cr, per official filings.

What is the share price of Eris Lifesciences (ERIS)?

Eris Lifesciences last traded at ₹1,440.60 (-1.6% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Eris Lifesciences

ERIS · NSE · Pharma · India

₹1,440.60-1.6%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 10:00 AM

Snapshot

TickerERIS

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

HeadquartersAhmedabad, India

Market cap₹19,964 Cr

P/B5.0

Volume80.09K

Websitewww.eris.co.in

Filings tracked0

About Eris Lifesciences

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters69.7%
Institutions22.9%
Public & other7.4%

55 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

Margin has compressed by about 2.9 points over the period — profitability is trending down.

Net margin trend22.7% → 19.8%

Margin has compressed by about 2.9 points over the period — profitability is trending down.

Growth qualityrev 23% · PAT 17%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹888 Cr

Next fiscal year

Rev ₹4,129 Cr · EPS 61.14

Est. earnings growth +30.1%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹1,200.0052-wk range₹1,885.00

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹19,964 Cr

Day change

-1.6%

Fwd P/E

23.6

P/B

5.0

Div yield

0.98%

Beta

-0.11

Revenue (FY2026)

₹3,129 Cr

Net margin

19.8%

Revenue CAGR (3y)

+22.9%

Profit CAGR (3y)

+17.5%

Net profit (FY2026)

₹620 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about ERIS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹3,129 Cr	₹620 Cr	19.8%
FY2025	₹2,894 Cr	₹352 Cr	12.2%
FY2024	₹2,009 Cr	₹392 Cr	19.5%
FY2023	₹1,685 Cr	₹382 Cr	22.7%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹757 Cr	₹282 Cr	37.2%
2025Q4	₹807 Cr	₹100 Cr	12.3%
2025Q3	₹792 Cr	₹120 Cr	15.2%
2025Q2	₹773 Cr	₹118 Cr	15.3%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.